Stryker Ramps Up Compliance Spending, But Predicts Unimpeded Growth
This article was originally published in The Gray Sheet
Executive Summary
Stryker is raising its stake in compliance activities in response to government scrutiny of its regulatory and sales practices, but the firm does not foresee a major hit to its bottom line
You may also be interested in...
Ortho Earnings: Stryker Plans Big Compliance Investment In 2009
Stryker will spend between $60 million and $90 million on compliance initiatives in 2009, as it overhauls its quality standards and resolves issues related to three outstanding FDA warning letters
Ortho Earnings: Stryker Plans Big Compliance Investment In 2009
Stryker will spend between $60 million and $90 million on compliance initiatives in 2009, as it overhauls its quality standards and resolves issues related to three outstanding FDA warning letters
Biomet U.S. Hip Sales Advance 14% In Q1; Spine Revenues “Essentially Flat”
Biomet's accelerated U.S. hip sales growth of 14% for its most recent fiscal quarter is attributable in part to difficulties facing its competitors, as well as the strength of products like its Taperloc hip system, M2a-Magnum acetabular system and E-Poly acetabular liners, according to the company